Zhaoyi Feng
About Zhaoyi Feng
Zhaoyi Feng is a Senior Physician II at BeiGene with over a decade of experience in the medical field, including roles at Massachusetts General Hospital and Harvard Medical School.
Company
Zhaoyi Feng currently works at BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. He joined BeiGene in September 2017 and holds the position of Senior Physician II. His role likely involves significant involvement in clinical development and research initiatives within the company.
Title
Zhaoyi Feng holds the title of Senior Physician II at BeiGene. This position signifies a high level of responsibility and expertise in the medical field, particularly in clinical and research capacities pertinent to oncology and drug development.
Education and Expertise
Zhaoyi Feng has extensive experience in both clinical and research settings. He completed his residency at Peking University First Hospital from 2010 to 2015, gaining invaluable clinical experience over five years. He then served as an attending doctor at the same institution for two years. Additionally, Feng has held postdoctoral research fellowships at Massachusetts General Hospital and Harvard Medical School, further enhancing his research expertise.
Background
Zhaoyi Feng has over a decade of experience in the medical field, covering both clinical practice and medical research. His career includes roles at prestigious institutions like Massachusetts General Hospital, Harvard Medical School, and Peking University First Hospital. His background includes work as a postdoctoral research fellow and an attending doctor, showcasing a blend of clinical and academic prowess.
Achievements
Throughout his career, Zhaoyi Feng has taken on significant leadership responsibilities, including serving as Vice President of the Chinese Staff and Scholar Association at Massachusetts General Hospital in 2017. His roles have spanned top-tier medical institutions, contributing to both clinical and research advancements. Joining BeiGene in 2017, he has continued to leverage his experience in a role that demands high expertise and leadership in the field of medical oncology.